close_game
close_game

Sputnik V 75% effective against Omicron: Vaccine developer

Updated On Jan 18, 2022 05:38 PM IST
  • The Sputnik V effectiveness against Omicron decreases by eight times but it is still enough for protection, Alexander Gintsburg said, adding that the effectiveness of other vaccines decreases by 21 times.
1 / 5
The head of Russia's Gamaleya Research Center, Alexander Gintsburg, on Tuesday said that the effectiveness of the Sputnik V Covid-19 vaccine against the Omicron coronavirus variant is 75 per cent. expand-icon View Photos in a new improved layout
Updated on Jan 18, 2022 05:38 PM IST

The head of Russia's Gamaleya Research Center, Alexander Gintsburg, on Tuesday said that the effectiveness of the Sputnik V Covid-19 vaccine against the Omicron coronavirus variant is 75 per cent.

2 / 5
"In the population, the effectiveness of the Sputnik V vaccine in relation to Omicron ... is 75 per cent," Alexander Gintsburg said in the Rossiya Segodnya press center. expand-icon View Photos in a new improved layout
Updated on Jan 18, 2022 05:38 PM IST

"In the population, the effectiveness of the Sputnik V vaccine in relation to Omicron ... is 75 per cent," Alexander Gintsburg said in the Rossiya Segodnya press center.

3 / 5
“Protection against Omicron increases to 100% if a person receives a Sputnik Light booster dose in six months but decreases to 56-57% if revaccination is not done," he further said about the booster dose. expand-icon View Photos in a new improved layout
Updated on Jan 18, 2022 05:38 PM IST

“Protection against Omicron increases to 100% if a person receives a Sputnik Light booster dose in six months but decreases to 56-57% if revaccination is not done," he further said about the booster dose.

4 / 5
Last week, Hyderabad-based biotechnology firm Bharat Biotech also said that the "Booster dose of Covaxin generated robust neutralising antibody responses against both Omicron and Delta variants of SARS-CoV-2. expand-icon View Photos in a new improved layout
Updated on Jan 18, 2022 05:38 PM IST

Last week, Hyderabad-based biotechnology firm Bharat Biotech also said that the "Booster dose of Covaxin generated robust neutralising antibody responses against both Omicron and Delta variants of SARS-CoV-2.

5 / 5
"The neutralisation activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant," Bharat Biotech said in a statement. expand-icon View Photos in a new improved layout
Updated on Jan 18, 2022 05:38 PM IST

"The neutralisation activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant," Bharat Biotech said in a statement.

SHARE
Story Saved
Live Score
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Saturday, October 12, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On